Terumo Medical Corporation Announces its Program for the Global Embolization Symposium and Technologies (GEST) Meeting

Terumo Medical Corporation Announces its Program for the Global Embolization Symposium and Technologies (GEST) Meeting. Focus is on Benefit of Embolization Using AZUR® Peripheral Hydrocoil® System

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Somerset, NJ (PRWEB) May 5, 2010

Terumo Medical Corporation, a U.S.-based subsidiary of Terumo Corporation, today announced its educational program for the 4th Annual Global Embolization Symposium and Technologies (GEST) Meeting, May 6 to 9, in San Francisco, CA.
Terumo’s primary focus at this meeting is the AZUR® Peripheral Hydrocoil® Embolization System.

GEST, which is the largest embolization meeting of its kind, is being held in the United States for the first time. Terumo is one of three primary sponsors of the 2010 meeting.

Terumo will host a lunchtime symposium on Thursday, May 6, beginning at 12:00 p.m. The program will feature three prominent physicians, including the first presentation of Dr. Craig Greben’s recently published article in Vascular and Endovascular Surgery (44(3) 217-222, March 2010) on the Double Micro Catheter Technique:    

  •     Watertight Occlusion of the Gastroduodenal Artery. Steven C. Rose, M.D. Professor of Clinical Radiology, Section Chief Interventional Oncology, University of California, San Diego Medical Center, San Diego, California.
  •     AZUR in the Periphery: The MUSC Experience. Marcelo Guimaraes, M.D. Assistant Professor, Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, South Carolina.
  •     The Use of Hydrogel Coated Coils in the Periphery: The North Shore Medical Center Experience. Craig Greben, M.D. Chief, Division of Vascular and Interventional Radiology, North Shore University Hospital, Manhasset, New York.

“Detachable coil technology has significantly expanded the treatment pool of patients I can intervene on safely,” said Dr. Greben. “It provides for precise placement and significantly impacts my clinical options.”

GEST attendees will have the opportunity to gain hands-on experience with Terumo’s AZUR Detachable 35, the first of its kind and Terumo’s latest embolic product. The Detachable 35 affords the same control as the Detachable 18, but provides more volume, thereby expanding treatment opportunities in areas like pre-EVAR embolization (hypogastrics), aneurysms, arterio-venous malformations (AVMs), arterio-venous fistulas (AVFs), among others.

“We are proud to support this international meeting and to demonstrate Terumo’s commitment to the market, as well as our dedication to bringing forward new technologies that can improve patient outcomes and expand a physician’s treatment options,” said Fernando Yuste, Senior Marketing Manager, Terumo Interventional Systems. “We look forward to introducing the AZUR Detachable 35 at this meeting.”

Terumo Associates will be available at the Terumo exhibit booth (#20) to answer questions and to engage with healthcare professionals interested in experiencing the AZUR Detachable 35 in particular and other AZUR technologies in a vessel model. In addition, there are two one-hour “Hands-on Sessions”, which will include AZUR products, held on May 6 at 1:45 p.m. and 2:45 p.m.

Terumo Interventional Systems

Terumo Interventional Systems (TIS), a strategic business unit of Terumo Medical Corporation, directly markets a full line of guidewires, catheters, introducer sheaths, guiding sheaths and embolization products for use in a multitude of different interventional procedures.

Interventional Radiologists, Interventional Neuroradiologists, Interventional Cardiologists, and Vascular Surgeons are among the medical professionals that depend upon TIS products to access and cross difficult-to-reach lesions, thereby allowing therapeutic intervention in previously unreachable vascular beds.

For more information, customers can contact Terumo Interventional Systems by calling its Inside Sales Team at 800.862.4143 or visit http://www.terumois.com.

Terumo Medical Corporation

Founded in 1972 as a Terumo Corporation subsidiary, Terumo Medical Corporation (TMC) develops, manufactures, and markets high-quality medical devices used in a broad range of applications in numerous healthcare markets. TMC manufactures a broad portfolio of needles and syringes, entry-site management products, and a line of sterile connection devices used in hospitals and blood banks worldwide.

Terumo Corporation

Tokyo-based Terumo Corporation is one of the world’s leading medical device manufacturers with $3.0 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation’s shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol , or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan’s leading stock index.

###


Contact